Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRigano, Joseph-
dc.contributor.authorNg, Cheryl-
dc.contributor.authorNandurkar, Harshal-
dc.contributor.authorHo, Prahlad-
dc.identifier.citationBlood Coagulation & Fibrinolysis 2018; 29(2): 148-154en_US
dc.description.abstractDirect oral anticoagulants (DOACs) are increasingly being used, primarily due to their drug stability and patient convenience. Although these drugs have been evaluated to be well tolerated in numerous clinical trials, their impact on in-vivo anticoagulation effect, variability and therapeutic drug level remains unknown. Hence, we aim to study the effect and variability of DOACs on thrombin generation via the calibrated automated thrombogram. Anonymized coagulation specimens from outpatients on warfarin were collected. Pooled normal plasma samples were spiked with increasing concentrations of dabigatran, rivaroxaban and apixaban. Similarly, plasma samples with normal coagulation profiles were spiked with two concentrations each of dabigatran, rivaroxaban and apixaban. Thrombin generation via calibrated automated thrombogram was run using the above samples and compared with a dataset of normal controls. Increasing international normalized ratio was associated with a reduction of endogenous thrombin potential (ETP) and thrombin peak and increasing lag time. Factor Xa inhibitors produced a flattened thrombin generation curve with a reduction of thrombin peak and relative preservation of ETP. Direct thrombin inhibitors produced a reduction of both ETP and thrombin peak and increasing lag time. Seventy-one citrated plasma samples (26 dabigatran, 21 rivaroxaban and 24 apixaban) were evaluated. The two concentrations produced a reduction of thrombin generation parameters with significant interindividual variability compared with neat plasma of 35-93, 13-31 and 18-71% and for dabigatran, rivaroxaban and apixaban, respectively. Thrombin generation can measure the anticoagulation effect of commonly used DOACs, with each drug having a unique thrombin generation profile. The variability noted using the same concentration suggests significant interindividual pharmacodynamic differences, which maybe relevant with respect to efficacy as well as bleeding side effects. Further delineation of the modifiers of interindividual differences is required in the in-vivo setting.en_US
dc.titleThrombin generation estimates the anticoagulation effect of direct oral anticoagulants with significant interindividual variability observeden_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBlood Coagulation & Fibrinolysisen_US
dc.identifier.affiliationAustin Pathology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Clinical Haematology, Northern Health, Epping, Victoria, Australiaen_US
dc.identifier.affiliationAustralian Centre for Blood Disease, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australiaen_US
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 27, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.